New York, December 1, 2025 – Inpart, the leading end-to-end platform for biopharma partnering, announces a key addition to its leadership team as it enters the next phase of commercial expansion. As pharmaceutical companies increase reliance on external innovation, AI is reshaping how opportunities are discovered and advanced to patients. In response, Inpart has invested more than $40 million over the past four years into R&D to build an AI-enabled platform to source, evaluate and manage external innovation, setting the stage for accelerated commercial growth.
To support this momentum, Inpart is proud to welcome into its senior leadership team, Ibraheem Mahmood as Board Strategy Lead.
Ibraheem brings a broad background in medicine, finance, biotech, and clinical technology. After studying medicine at Oxford University, he began his career in life sciences investment banking at Nomura and later led life sciences equity research at Investec. He co-founded DrugDev, raising $70 million and scaling the company to nearly 1,000 employees before its acquisition by IQVIA, where he then served as Global Head of Clinical Technology. Ibraheem went on to co-found AMO Pharma, securing over $100 million in funding for its neurodevelopmental programs, and co-founded Induction Healthcare, whose technology now supports more than 50,000 clinicians daily. He also held Operating Partner roles at Abingworth and Oxford Sciences.
“Partnering is what we do in our industry, and Inpart leads this space and makes it fly with AI. I’m excited to join the team and get involved!” commented Ibraheem.
“Our product is ready, and the time is now,” said Gilles Toulemonde, CEO of Inpart. “As the leading platform used by the majority of top global pharma companies, we’re scaling our commercial footprint and building the talent required to ensure our platform remains the most trusted foundation for pharma partnering technology.”
Backed by Carlyle, a strengthened leadership bench, and a laser focus on AI-powered transformation, Inpart is poised to redefine how pharma R&D partnerships are sourced, managed, and scaled.
About Inpart
Biopharma teams rely on Inpart as their single source of truth that consolidates opportunity discovery, evaluation, and alliance management into a unified platform. Used by 70% of the world’s top 50 pharmaceutical companies, Inpart supports thousands of active collaborations and interactions each year. By bringing data, workflows, and AI-driven insights together in one place, customers gain clearer visibility, faster decision cycles, and a more predictable path to turning external innovation into pipeline value.
Contact Sarah Issa, Chief Marketing Officer at Inpart sarah.issa@inpart.io +33 6 24 86 81 69